Mass Eradication of Helicobacter pylori to Prevent Gastric Cancer: Theoretical and Practical Considerations

키워드

참고문헌 (88)

1. Jemal A, "Global cancer statistics", CA Cancer J Clin, 61, pp.69~90 (2011)
2. Ferlay J, "Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012", Int J Cancer, 136, pp.E359~E386 (2012)
3. Herrero R, "Prevention of gastric cancer", JAMA, 312, pp.1197~1198 (2014)
4. Jin Young Park, "Prevention Strategies for Gastric Cancer: A Global Perspective", Clinical Endoscopy, 47(6), pp.478~489 (2014), 대한소화기내시경학회
5. "All nobel prizes in physiology or medicine" (2015)[URL]
6. Fox JG, "Inflammation, atrophy, and gastric cancer", J Clin Invest, 117, pp.60~69 (2007)
7. Helicobacter pylori eradication as a strategy for preventing gastric cancer, "IARC Helicobacter pylori Working Group", International Agency for Research on Cancer, ~, pp.IARC Working Group Reports, No. 8 (2014)
8. Sugano K, "Kyoto global consensus report on Helicobacter pylori gastritis", Gut, 64, pp.1353~1367 (2015)
9. Graham DY, "The time to eradicate gastric cancer is now", Gut, 54, pp.735~738 (2005)
10. Lee YC, "The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention", Gut, 62, pp.676~682 (2013)
11. Lee YC, "Accuracy of faecal occult blood test and Helicobacter pylori stool antigen test for detection of upper gastrointestinal lesions", BMJ Open, 3, pp.e003989~ (2013)
12. Wilson JM, "Principles and practice of screening for disease", WHO Chron, 22, pp.473~ (1968)
13. "Cancer statistics" (2008)[URL]
14. Bray F, "Global estimates of cancer prevalence for 27 sites in the adult population in 2008", Int J Cancer, 132, pp.1133~1145 (2013)
15. Wu GH, "Number of screens for overdetection as an indicator of absolute risk of overdiagnosis in prostate cancer screening", Int J Cancer, 131, pp.1367~1375 (2012)
16. Yachida S, "Distant metastasis occurs late during the genetic evolution of pancreatic cancer", Nature, 467, pp.1114~1117 (2010)
17. Patz EF Jr, "Overdiagnosis in low-dose computed tomography screening for lung cancer", AMA Intern Med, 174, pp.269~274 (2014)
18. Sanduleanu S, "Definition and taxonomy of interval colorectal cancers: a proposal for standardising nomenclature", Gut, 64, pp.1257~1267 (2015)
19. Chiang TH, "Difference in performance of fecal immunochemical tests with the same hemoglobin cutoff concentration in a nationwide colorectal cancer screening program", Gastroenterology, 147, pp.1317~1326 (2014)
20. Garland SM, "Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases", N Engl J Med, 356, pp.1928~1943 (2007)
21. Chang MH, "Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group", N Engl J Med, 336, pp.1855~1859 (1997)
22. Martel C, "Global burden of cancers attributable to infections in 2008: a review and synthetic analysis", Lancet Oncol, 13, pp.607~615 (2012)
23. Wong BC, "Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial", JAMA, 291, pp.187~194 (2004)
24. Correa P, "Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-helicobacter pylori therapy", J Natl Cancer Inst, 92, pp.1881~1888 (2000)
25. Mera R, "Long term follow up of patients treated for Helicobacter pylori infection", Gut, 54, pp.1536~1540 (2005)
26. You WC, "Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions", J Natl Cancer Inst, 98, pp.974~983 (2006)
27. Li WQ, "Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups", J Natl Cancer Inst, 106 (2014)
28. Leung WK, "Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication", Gut, 53, pp.1244~1249 (2004)
29. Zhou L., "Ten-year follow-up study on the incidence of gastric cancer and the pathological changes of gastric mucosa after H. pylori eradication in China", Gastroenterology, 134, pp.A233~ (2008)
30. Fukase K, "Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial", Lancet, 372, pp.392~397 (2008)
31. Ford AC, "Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials", BMJ, 348, pp.g3174~ (2014)
32. Yoon SB, "Effect of Helicobacter pylori eradication on metachronous gastric cancer after endoscopic resection of gastric tumors: a meta-analysis", Helicobacter, 19, pp.243~248 (2014)
33. Malfertheiner P, "Management of Helicobacter pylori infection: the Maastricht IV", Florence Consensus Report, 2012, pp.61, 646~664
34. Granstrom M, "Diagnosis of Helicobacter pylori", Helicobacter, 13(1), pp.7~12 (2008)
35. Gisbert JP, "Accuracy of monoclonal stool antigen test for the diagnosis of H. pylori infection: a systematic review and meta-analysis", Am J Gastroenterol, 101, pp.1921~1930 (2006)
36. Lee YC, "Performance of a one-step fecal sample-based test for diagnosis of Helicobacter pylori infection in primary care and mass screening settings", J Formos Med Assoc, 113, pp.899~907 (2014)
37. Loy CT, "Do commercial serological kits for Helicobacter pylori infection differ in accuracy? A meta-analysis", Am J Gastroenterol, 91, pp.1138~1144 (1996)
38. Benson VS, "Toward standardizing and reporting colorectal cancer screening indicators on an international level: the International Colorectal Cancer Screening Network", J Cancer, 130, pp.2961~2973 (2012)
39. Porras C, "Epidemiology of Helicobacter pylori infection in six Latin American countries (SWOG TrialS0701)", Cancer Causes Control, 24, pp.209~215 (2013)
40. Greenberg ER, "14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial", Lancet, 378, pp.507~514 (2011)
41. Peleteiro B, "Prevalence of Helicobacter pylori infection worldwide: a systematic review of studies with national coverage", Dig Dis Sci, 59, pp.1698~1709 (2014)
42. Lee YC, "A community-based study of Helicobacter pylori therapy using the strategy of test, treat, retest, and retreat initial treatment failures", Helicobacter, 11, pp.418~424 (2006)
43. Graham DY, "Helicobacter pylori: basic mechanisms to clinical cure 1998", pp.426~440 (1998), Springer
44. Liou JM, "Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial", Lancet, 381, pp.205~213 (2013)
45. Graham DY, "Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence", Clin Gastroenterol Hepatol, 12(e3), pp.177~186 (2014)
46. Lee SY, "Current progress toward eradicating Helicobacter pylori in East Asian countries: differences in the 2013 revised guidelines between China, Japan, and South Korea", World J Gastroenterol, 20, pp.1493~1502 (2014)
47. Zullo A, "High eradication rates of Helicobacter pylori with a new sequential treatment", Aliment Pharmacol Ther, 17, pp.719~726 (2003)
48. Romano M, "Pretreatment antimicrobial susceptibility testing is cost saving in the eradication of Helicobacter pylori", Clin Gastroenterol Hepatol, 1, pp.273~278 (2003)
49. Vaira D, "Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial", Ann Intern Med, 146, pp.556~563 (2007)
50. Demir M, "Clarithromycin resistance and efficacy of clarithromycin-containing triple eradication therapy for Helicobacter pylori infection in type 2 diabetes mellitus patients", South Med J, 102, pp.1116~1120 (2009)
51. Romano M, "Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial", Gut, 59, pp.1465~1470 (2010)
52. Wu DC, "Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection", Clin Gastroenterol Hepatol, 8(e1), pp.36~41 (2010)
53. Sirimontaporn N, "Ten-day sequential therapy of Helicobacter pylori infection in Thailand", Am J Gastroenterol, 105, pp.1071~1075 (2010)
54. Yakoob J, "Antibiotic susceptibility patterns of Helicobacter pylori and triple therapy in a high-prevalence area", Br J Biomed Sci, 67, pp.197~201 (2010)
55. Hsu PI, "Is there a benefit to extending the duration of Helicobacter pylori sequential therapy to 14 days?", Helicobacter, 16, pp.146~152 (2011)
56. Malfertheiner P, "Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial", Lancet, 377, pp.905~913 (2011)
57. Mahachai V, "Sequential therapy in clarithromycin-sensitive and -resistant Helicobacter pylori based on polymerase chain reaction molecular test", J Gastroenterol Hepatol, 26, pp.825~828 (2011)
58. Molina-Infante J, "Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance", Gastroenterology, 145(e1), pp.121~128 (2013)
59. "What is an “organized” screening programme" (2015)[URL]
60. Liou JM, "Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial", J Antimicrob Chemother, 68, pp.450~456 (2013)
61. Graham DY, "Helicobacter pylori treatment in the era of increasing antibiotic resistance", Gut, 59, pp.1143~1153 (2010)
62. Briggs AH, "O’Brien BJ. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease", Med Decis Making, 22, pp.290~308 (2002)
63. Lee YC, "Cost-effectiveness analysis between primary and secondary preventive strategies for gastric cancer", Cancer Epidemiol Biomarkers Prev, 16, pp.875~885 (2007)
64. Parsonnet J, "Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials", Lancet, 348, pp.150~154 (1996)
65. Fendrick AM, "Clinical and economic effects of population-based Helicobacter pylori screening to prevent gastric cancer", Arch Intern Med, 159, pp.142~148 (1999)
66. Harris RA, "Helicobacter pylori and gastric cancer: what are the benefits of screening only for the CagA phenotype of H. pylori?", Helicobacter, 4, pp.69~76 (1999)
67. Mason J, "The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial", Aliment Pharmacol Ther, 16, pp.559~568 (2002)
68. Roderick P, "Cost-effectiveness of population screening for Helicobacter pylori in preventing gastric cancer and peptic ulcer disease, using simulation", J Med Screen, 10, pp.148~156 (2003)
69. Wang Q, "Cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: Markov decision analysis", Zhonghua Liu Xing Bing Xue Za Zhi, 24, pp.135~139 (2003)
70. Xie F, "Cost effectiveness analysis of population-based serology screening and (13)C-Urea breath test for Helicobacter pylori to prevent gastric cancer: a markov model", World J Gastroenterol, 14, pp.3021~3027 (2008)
71. Xie F, "Illustrating economic evaluation of diagnostic technologies: comparing Helicobacter pylori screening strategies in prevention of gastric cancer in Canada", J Am Coll Radiol, 6, pp.317~323 (2009)
72. Yeh JM, "Exploring the cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer in China in anticipation of clinical trial results", Int J Cancer, 124, pp.157~166 (2009)
73. Ford AC, "A community screening program for Helicobacter pylori saves money: 10-year follow-up of a randomized controlled trial", Gastroenterology, 129, pp.1910~1917 (2005)
74. Chow WH, "An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma", Cancer Res, 58, pp.588~590 (1998)
75. Chen Y, "Helicobacter pylori colonization is inversely associated with childhood asthma", J Infect Dis, 198, pp.553~560 (2008)
76. Wu MS, "A case-control study of association of Helicobacter pylori infection with morbid obesity in Taiwan", Arch Intern Med, 165, pp.1552~1555 (2005)
77. Papamichael K, "Helicobacter pylori infection and inflammatory bowel disease: is there a link?", World J Gastroenterol, 20, pp.6374~6385 (2014)
78. de Jong BC, "Infection with Helicobacter pylori is associated with protection against tuberculosis", PLoS ONE, 5, pp.e8804~ (2010)
79. Graham DY, "Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits", Gastroenterology, 148(e3), pp.719~731 (2015)
80. Lee YC, "The effect of metabolic risk factors on the natural course of gastro-oesophageal reflux disease", Gut, 58, pp.174~181 (2009)
81. Yaghoobi M, "Is there an increased risk of GERD after Helicobacter pylori eradication? A meta-analysis", Am J Gastroenterol, 105, pp.1007~1013 (2010)
82. Wald NJ, "When can a risk factor be used as a worthwhile screening test?", BMJ, 319, pp.1562~1565 (1999)
83. Dan YY, "Endoscopic screening for gastric cancer", Clin Gastroenterol Hepatol, 4, pp.709~716 (2006)
84. Shiotani A, "Eradication of gastric cancer is now both possible and practical", Semin Cancer Biol, 23(6 Pt B), pp.492~501 (2013)
85. Rugge M, "OLGA staging for gastritis: a tutorial", Dig Liver Dis, 40, pp.650~658 (2008)
86. Guyatt GH, "GRADE guidelines: 4. rating the quality of evidence: study limitations (risk of bias)", J Clin Epidemiol, 64, pp.407~415 (2011)
87. Choi HS, "Combining the serum pepsinogen level and Helicobacter pylori antibody test for predicting the histology of gastric neoplasm", J Dig Dis, 15, pp.293~298 (2014)
88. Fock KM, "Helicobacter pylori research: historical insights and future directions", Nat Rev Gastroenterol Hepatol, 10, pp.495~500 (2013)

관련 논문AI추천